Trevi Therapeutics Inc

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization Haduvio to treat serious neurologically mediated conditions. It includes treatment of chronic pruritus associated with prurigo nodularis and chronic cough in patients with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in patients with Parkinson’s disease. The company was founded by Thomas R. Sciascia and Jennifer L. Good in March 2011 and is headquartered in New Haven, CT.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Trevi Therapeutics reports transformative year with strong financial position

Trevi Therapeutics' strong performance in 2022, backed by positive trial results and financial stability, sets the stage for continued growth.
While facing challenges such as potential delays and increased expenses, Trevi's strategic planning and diverse opportunities position the company for success.
By leveraging its strengths in clinical development and upcoming data releases, Trevi aims to build scientific evidence and attract potential partners.
Overall, Trevi's focus on advancing its pipeline and showcasing trial results highlights its commitment to addressing unmet medical needs.

Trevi Therapeutics advances Haduvio trials, navigates regulatory challenges for growth

Trevi Therapeutics showcased progress in Haduvio's clinical development and financial stability despite a net loss.
The company faces challenges in dosing strategies, patent coverage, and regulatory hurdles but is poised for growth through strategic initiatives.

Trevi Therapeutics advances Haduvio in chronic cough, overcomes financial hurdles

Trevi Therapeutics is progressing with Haduvio's development in chronic cough indications
Financially, the company is managing its resources prudently and eliminating debt
Challenges persist with study delays due to supply shortages, but opportunities for growth are evident

Trevi Therapeutics advances Haduvio trials amidst financial stability

Trevi Therapeutics' financials show resilience with a focus on clinical advancements.
Challenges in trial planning and FDA outcomes require strategic navigation.
Opportunities for growth lie in upcoming trials and conference participation.
Overall, Trevi Therapeutics is positioned for continued progress and innovation.

Trevi Therapeutics advances novel cough treatments amidst financial challenges

Trevi Therapeutics is advancing innovative treatments for refractory chronic cough. Despite financial challenges, the company's strong cash position and ongoing clinical trials position it well for future growth.

Trevi Therapeutics reports Q1 loss, progresses in clinical trials

Trevi Therapeutics faces challenges with timelines for top line data in ongoing trials but holds promise in clinical development.
The company's financial performance reflects increased R&D expenses but maintains a strong cash position for future growth.

Trevi Therapeutics reports Q2 loss, advances in key trials

Trevi Therapeutics' Q2 2024 performance reflects ongoing investment in research with a net loss of $12.4 million and R&D expenses at $10 million.
Management's strategic focus on IPF and RCC trials, along with new leadership appointments and study initiations, underpin the company's commitment to therapeutic advancements.
While facing challenges like enrollment imbalances and financial pressures, Trevi Therapeutics remains poised for growth with upcoming data readouts and a strong research pipeline.

Trevi Therapeutics reports Q3 loss, eyes upcoming milestones and trials

Trevi Therapeutics is navigating increased R&D expenses, with a strong cash position and clear focus on upcoming data milestones. Analyst inquiries and ongoing trials present challenges, while opportunities lie in defining patient populations and regulatory decisions post-NDA submission.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

NEW HAVEN, Conn., Nov. 3, 2021 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of an investigational therapy Haduvio™ (nalbuphine ER) to treat serious neurologically mediated conditions, today announced that management will host a conference call and live audio webcast on Wednesday, November 10 at 4:30 p.m.

Trevi Therapeutics to Report Q3 2021 Financial Results and Provide a Corporate Update on Wednesday, November 10, 2021

NEW HAVEN, Conn., Oct. 13, 2021 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio™ (nalbuphine ER) to treat serious neurologically mediated conditions, today announced that Dr. Bill Forbes, Chief Development Officer, will present as part of a virtual viewpoint session at the 11th World Congress on Itch (WCI) taking place from October 22-23, 2021.

Trevi Therapeutics to Present at 11th World Congress on Itch (WCI)

Aikido Pharma Inc.

9 Meters Biopharma

Progenity

Selecta Biosciences

Will these penny stocks meet analysts' expectations? The post 5 Top Penny Stocks Analysts Say To Buy Now With 123%-733% Targets appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

5 Top Penny Stocks Analysts Say To Buy Now With 123%-733% Targets

The stock price of Trevi Therapeutics Inc (NASDAQ: TRVI) increased by over 35% pre-market today. This is why it happened.

TRVI Stock: Why It Increased Today

NEW HAVEN, Conn., Oct. 7, 2021 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio™ (nalbuphine ER) to treat serious neurologically mediated conditions, today announced that senior management will be available for virtual one-on-one meetings at Alliance Global Partners' Virtual Biotech & Specialty Pharma Conference taking place October 13, 2021.

Trevi Therapeutics Participating in Alliance Global Partners' Virtual Biotech & Specialty Pharma Conference

NEW HAVEN, Conn., Sept. 30, 2021 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of an investigational therapy Haduvio™ (nalbuphine ER) to treat serious neurologically mediated conditions, today announced that it has entered into a definitive agreement with a healthcare-focused institutional investor, for the purchase, in a private placement priced at-the-market under Nasdaq rules, of (i) 2,373,201 shares of common stock and accompanying warrants to purchase an aggregate of 4,746,402 shares of common stock, and (ii) pre-funded warrants to purchase up to an aggregate of 4,926,069 shares of common stock and accompanying warrants to purchase an aggregate of 9,852,138 shares of common stock.

Trevi Therapeutics Announces $11.8 Million Private Placement Priced At-the-Market

Trevi Therapeutics, Inc. (TRVI) CEO Jennifer Good on Q2 2021 Results - Earnings Call Transcript

NEW HAVEN, Conn., Aug. 12, 2021 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of an investigational therapy Haduvio™ (nalbuphine ER) to treat serious neurologically mediated conditions, today announced financial results for the quarter ended June 30, 2021, as well as business updates.

Trevi Therapeutics Announces Second Quarter 2021 Financial Results and Business Update

NEW HAVEN, Conn., Aug. 9, 2021 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio™ (nalbuphine ER) to treat serious neurologically mediated conditions, today announced the appointment of Lisa Delfini, CPA, as Chief Financial Officer and Danine Summers, as Vice President, Medical Affairs.

Trevi Therapeutics Announces Additions to the Senior Leadership Team

NEW HAVEN, Conn., Aug. 5, 2021 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of an investigational therapy Haduvio™ (nalbuphine ER) to treat serious neurologically mediated conditions, today announced that management will host a conference call and live audio webcast on Thursday, August 12 at 4:30 p.m.

Trevi Therapeutics to Report Q2 2021 Financial Results on August 12

NEW HAVEN, Conn., June 9, 2021 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio™ (nalbuphine ER) to treat serious neurologically mediated conditions, today announced that Jennifer Good, President and CEO, has been selected to deliver a company presentation at 2021 BIO Digital.

Trevi Therapeutics to Present at 2021 BIO Digital Conference

Trevi Therapeutics' (TRVI) CEO Jennifer Good on Q1 2021 Results - Earnings Call Transcript

NEW HAVEN, Conn., May 13, 2021 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio™ (nalbuphine ER) to treat serious neurologically mediated conditions, today announced financial results for the quarter ended March 31, 2021, as well as business updates.

Trevi Therapeutics Announces First Quarter 2021 Financial Results and Business Update

NEW HAVEN, Conn., May 6, 2021 /PRNewswire/ -- Trevi Therapeutics, Inc. (NASDAQ: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of an investigational therapy Haduvio™ (nalbuphine ER) to treat serious neurologically mediated conditions, today announced that management will host a conference call and live audio webcast on Thursday, May 13 at 4:30 p.m.

Trevi Therapeutics to Report Q1 2021 Financial Results on May 13

NEW HAVEN, Conn., April 07, 2021 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of Haduvio™ (nalbuphine ER) to treat serious neurologically mediated conditions, today announced that management will participate in a virtual fireside chat, as well as host investor meetings, at the 20th Annual Needham Virtual Healthcare Conference on April 14, 2021. Trevi's presentation is scheduled for 2:15 p.m. ET.

Trevi Therapeutics to Present at 20th Annual Needham Virtual Healthcare Conference

Trevi Therapeutics, Inc. (TRVI) CEO Jennifer Good on Q4 2020 Results - Earnings Call Transcript

Expects to Complete Enrollment and Report Top-Line Data of the Phase 2b/3 PRISM Trial in Second Half of 2021

Trevi Therapeutics Announces Fourth Quarter and Year End 2020 Financial Results and Business Updates

Conference Call and Webcast to be Held at 4:30 p.m. ET Conference Call and Webcast to be Held at 4:30 p.m. ET

Trevi Therapeutics to Report Q4 and Year End 2020 Financial Results on March 25

As of late, it has definitely been a great time to be an investor in Trevi Therapeutics (TRVI).

Trevi Therapeutics' (TRVI) Shares March Higher, Can It Continue?

Industry Veteran to Lead the Clinical Development of Haduvio™ in Multiple Indications

Trevi Therapeutics Appoints William Forbes, Pharm.D. as Chief Development Officer

Trevi Therapeutics' (TRVI) CEO Jennifer Good on Q3 2020 Results - Earnings Call Transcript

PRISM Trial of Haduvio ™ for Severe Pruritus in Patients with Prurigo Nodularis 

Trevi Therapeutics Announces Third Quarter 2020 Financial Results and Business Update

NEW HAVEN, Conn., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of Haduvio™ (nalbuphine ER) to treat serious neurologically mediated conditions, today announced that management will present a Company overview, as well as host virtual investor meetings, at the Stifel 2020 Virtual Healthcare Conference on November 17, 2020.

Trevi Therapeutics to Present at Stifel Healthcare Conference

Trevi Therapeutics to Report Q3 2020 Financial Results on November 11

Expands Management Team to Support Clinical Development and Commercial Strategy of Haduvio™ in Multiple Late Stage Programs Expands Management Team to Support Clinical Development and Commercial Strategy of Haduvio™ in Multiple Late Stage Programs

News for Trevi Therapeutics Inc Stock (TRVI)